NOVEL oral anticoagulants
(NOACs) for prevention of stroke
or systemic embolism in nonvalvular
atrial fibrillation has
matched projections in the second
year of listing, although the first
year overestimated its demand,
according to the latest Drug
Utilisation Sub-Committee (DUSC)
of the Pharmaceutical Benefits
Advisory Committee (PBAC).
Metastatic castration resistant
prostate cancer therapies, fixed
dose combination treatments
for glaucoma and biological
disease-modifying anti-rheumatic
drugs (bDMARDs) for ankylosing
spondylitis were also reviewed as
well as treatments to be evaluated
against predicted use in future
DUSC meetings.
Go to www.pbs.gov.au for details.The above article was sent to subscribers in Pharmacy Daily's issue from 12 Aug 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Aug 16
PEAK pharmacy bodies are calling on the Australian Government to extend the new Commonwealth Prac Payment to pharmacy students, citing the challenges of “placement poverty” in unpaid practical placements.
AFT Pharmaceuticals is set to develop a topical treatment for keloid and hypertrophic scarring in partnership with NZ’s Massey Ventures, the commercialisation arm of Massey University, and the Gillies McIndoe Research Institute.
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.